Renaissance Technologies
BRNS

Renaissance Technologies’s Barinthus Biotherapeutics BRNS Stock Holding History

Renaissance Technologies’s Portfolio BRNS Stock Details BRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-25,000
Closed -$16.5K – 3213
2026
Q2 		$16.5K Sell
25,000
-126,000
-83% -$82.1K ﹤0.01% 3106
2026
Q1 		$85.9K Buy
151,000
+7,900
+6% +$5.21K ﹤0.01% 3050
2025
Q4 		$100K Buy
143,100
+76,800
+116% +$76.7K ﹤0.01% 3014
2025
Q3 		$82.9K Buy
66,300
+30,000
+83% +$37.5K ﹤0.01% 3277
2025
Q2 		$33.8K Buy
36,300
+600
+2% +$524 ﹤0.01% 3429
2025
Q1 		$34.7K Buy
35,700
+600
+2% +$616 ﹤0.01% 3325
2024
Q4 		$42.4K Buy
35,100
+7,200
+26% +$8.38K ﹤0.01% 3411
2024
Q3 		$33.2K Buy
27,900
+2,800
+11% +$3.76K ﹤0.01% 3389
2024
Q2 		$35.1K Sell
25,100
-2,600
-9% -$5.87K ﹤0.01% 3324
2024
Q1 		$66K Sell
27,700
-1,999
-7% -$5.64K ﹤0.01% 3441
2023
Q4 		$110K Buy
29,699
+8,299
+39% +$28K ﹤0.01% 3282
2023
Q3 		$66K Sell
21,400
-12,600
-37% -$27.1K ﹤0.01% 3341
2023
Q2 		$70K Buy
34,000
+22,600
+198% +$53.5K ﹤0.01% 3549
2023
Q1 		$26K Buy
+11,400
New +$31.7K ﹤0.01% 3779

Other funds holding BRNS

RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return

Renaissance Technologies's BRNS Position: Q3 2026 in Review

Renaissance Technologies sold out of Barinthus Biotherapeutics (BRNS) in Q3 2026, closing a stake of 25,000 shares — an estimated $16.5K sold.

Renaissance Technologies first reported a position in BRNS in Q1 2023 and held it in 14 quarters. The position peaked at $110K in Q4 2023. 1 fund tracked by Wall St. Rank holds BRNS as of Q3 2026.

  • Renaissance Technologies reported no remaining Barinthus Biotherapeutics position as of Q3 2026 after selling out during the quarter.
  • Renaissance Technologies sold 25,000 Barinthus Biotherapeutics shares in Q3 2026, an estimated $16.5K.
  • Renaissance Technologies first reported a position in Barinthus Biotherapeutics in Q1 2023 and held it in 14 quarters.
  • Renaissance Technologies's Barinthus Biotherapeutics position peaked at $110K in Q4 2023.
  • 1 fund tracked by Wall St. Rank held Barinthus Biotherapeutics as of Q3 2026.

Based on Renaissance Technologies's 13F filing for Q3 2026, filed 12 Nov 2026.